For decades, doctors have recognized the p53 gene for its tumor-suppressing properties. However, it was only in 2003 when the first p53-based anti-tumor drug was approved by China’s State Food and Drug Administration. Called Gendicine, the drug has since been used to treat over 16,000 cancer patients and more than 50 types of malignant cancers, and pre-cancerous lesions and cervical dysplasia.
Product Details
Gendicine comes in vials that contain 1,000,000,000,000 viral particles in 1.5 mL buffer solution. Its method of administration and amount of medication needed vary depending on the patient’s specific condition.
The Gendicine Advantage
Gendicine is unlike other cancer treatments currently available. Here are some of its proven benefits:
- It only targets cancer cells. No healthy cells are harmed in the process.
- Cancer cells do not develop resistance to gene therapy, so Gendicine’s effectiveness remains consistent.
- Cancer patients who received Gendicine have an overall response rate of 70%, which is much higher compared to chemotherapy.
- There are no serious side effects such as vomiting and hair loss. Most patients only report slight fevers that typically go away 2-6 hours after being injected with Gendicine.
- When combined with other forms of treatment, Gendicine helps increase tumor sensitivity to chemotherapy, radiotherapy, and hyperthermia therapy.
Want to know more about Gendicine? Contact us today!